UAE Peptide Vendor Blacklist: Red Flags for GCC Suppliers
Major US Peptide Regulation Update: What the New FDA Compounding Policy Means for BPC-157 and Five Other Peptides
Published: November 2026 | A Class Apart – Peptide News & Research
Big news for the peptide industry! A significant regulatory development in the United States could mark an important step forward for the future of peptide research and pharmacy compounding.
On 28 October 2026, the US Department of Health and Human Services (HHS) announced a new interim policy affecting six peptides, including the increasingly discussed BPC-157, TB-500 and MOTS-c.
Published in the Federal Register on 30 October, the announcement introduces greater flexibility for certain licensed US pharmacies and healthcare professionals preparing compounded peptide medicines.
But what exactly has changed, and what does it mean for the peptide industry?
Which Six Peptides Are Included?
The new HHS policy covers six compounds attracting growing scientific interest:
BPC-157 – Investigated for tissue repair, inflammation and recovery.
TB-500 – Studied for its potential involvement in tissue regeneration and healing.
KPV – A peptide being explored for its anti-inflammatory properties.
Epitalon – Investigated in ageing and cellular biology research.
Semax – A neuroactive peptide studied for potential cognitive and neurological effects.
MOTS-c – A mitochondrial-derived peptide attracting attention for metabolic regulation and energy metabolism.
Although these research areas are promising, clinical evidence remains limited, and these peptides have not been established as safe and effective treatments for these purposes.
What Has Changed in US Peptide Regulations?
The biggest development is the introduction of enforcement discretion.
Essentially, HHS has outlined circumstances in which it does not intend to pursue certain enforcement actions against eligible licensed pharmacies, physicians and federal facilities that compound medicines containing these peptides.
Pharmacy compounding involves preparing medicines to meet individual patients' needs.
However, this is not unrestricted permission to manufacture or sell peptides.
Participating professionals must satisfy specific conditions, including requirements surrounding ingredient sourcing, preparation, quality control and product testing.
The policy also restricts eligible compounded preparations to a single active ingredient.
Are BPC-157 and TB-500 Now FDA-Approved?
No – and this distinction is essential.
The policy does not grant FDA approval to BPC-157, TB-500, MOTS-c or the other three peptides.
Nor does it automatically add them to the FDA's official 503A Bulks List, which identifies certain substances eligible for pharmacy compounding under US legislation.
Instead, this interim approach provides limited regulatory flexibility while the authorities continue evaluating safety, quality and scientific evidence.
The policy may also change if new safety concerns emerge.
What Does This Mean for the Future of Peptides?
For researchers, healthcare professionals and the wider peptide industry, this represents a noteworthy regulatory development.
It suggests a willingness to consider controlled access to selected peptides through properly regulated pharmacy compounding, rather than treating every compound identically.
Nevertheless, significant questions remain regarding long-term safety, clinical effectiveness and future regulatory approval.
Importantly, US policy changes do not automatically affect peptide regulations in the UAE or other countries.
A New Chapter for Peptide Research?
At A Class Apart, we follow developments in peptide science and regulation closely.
This latest announcement highlights the importance of continued scientific investigation, product quality, transparency and responsible regulation.
While this is not full FDA approval, it is an important development worth watching as the regulatory landscape evolves.
Want to explore the official announcement?
Stay informed with the latest peptide research, scientific developments and regulatory news at A Class Apart.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice or imply that the peptides discussed are approved for human use.




Comments